These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 28540770)

  • 1. Transdermal estrogens in the changing landscape of hormone replacement therapy.
    Beck KL; Anderson MC; Kirk JK
    Postgrad Med; 2017 Aug; 129(6):632-636. PubMed ID: 28540770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transdermal hormone therapy and the risk of stroke and venous thrombosis.
    Speroff L
    Climacteric; 2010 Oct; 13(5):429-32. PubMed ID: 20670199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuation of postmenopausal hormone replacement therapy in a large health maintenance organization: transdermal matrix patch versus oral estrogen therapy.
    Ettinger B; Pressman A
    Am J Manag Care; 1999 Jun; 5(6):779-85. PubMed ID: 10538456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
    Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
    Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Basic principles of hormone replacement therapy in the postmenopause].
    Dören M
    Ther Umsch; 2000 Oct; 57(10):628-34. PubMed ID: 11081374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of continuation of postmenopausal hormone replacement therapy: transdermal versus oral estrogen.
    Ettinger B; Pressman A; Bradley C
    Menopause; 1998; 5(3):152-6. PubMed ID: 9774760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of transdermal nonpatch estrogen therapy for the management of menopausal symptoms.
    Carroll N
    J Womens Health (Larchmt); 2010 Jan; 19(1):47-55. PubMed ID: 20088658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What's new in hormone replacement therapy: focus on transdermal estradiol and micronized progesterone.
    Simon JA
    Climacteric; 2012 Apr; 15 Suppl 1():3-10. PubMed ID: 22432810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review.
    L'hermite M; Simoncini T; Fuller S; Genazzani AR
    Maturitas; 2008; 60(3-4):185-201. PubMed ID: 18775609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mammographic breast density during hormone replacement therapy: effects of continuous combination, unopposed transdermal and low-potency estrogen regimens.
    Lundström E; Wilczek B; von Palffy Z; Söderqvist G; von Schoultz B
    Climacteric; 2001 Mar; 4(1):42-8. PubMed ID: 11379377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17beta-estradiol and dydrogesterone.
    Lippuner K; Haenggi W; Birkhaeuser MH; Casez JP; Jaeger P
    J Bone Miner Res; 1997 May; 12(5):806-12. PubMed ID: 9144347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sex hormone replacement therapy and modulation of vascular function in cardiovascular disease.
    Koledova VV; Khalil RA
    Expert Rev Cardiovasc Ther; 2007 Jul; 5(4):777-89. PubMed ID: 17605655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different effects of transdermal and oral hormone replacement therapy on the renin-angiotensin system, plasma bradykinin level, and blood pressure of normotensive postmenopausal women.
    Ichikawa J; Sumino H; Ichikawa S; Ozaki M
    Am J Hypertens; 2006 Jul; 19(7):744-9. PubMed ID: 16814131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HRT management: the American experience.
    Carr BR
    Eur J Obstet Gynecol Reprod Biol; 1996 Apr; 64 Suppl():S17-20. PubMed ID: 8732468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transdermal estrogen therapy.
    Connell EB
    Postgrad Med; 1997 Jun; 101(6):115-6, 122, 128-30 passim. PubMed ID: 9194869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoparticle delivery for transdermal HRT.
    Valenzuela P; Simon JA
    Nanomedicine; 2012 Sep; 8 Suppl 1():S83-9. PubMed ID: 22640909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Investigation of atherosclerosis in postmenopausal women: alteration of atherosclerosis-associated factors and vascular atherosclerosis by oral and transdermal estrogen replacement].
    Sumino H; Murakami M
    Rinsho Byori; 2013 Mar; 61(3):256-62. PubMed ID: 23785796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HRT optimization, using transdermal estradiol plus micronized progesterone, a safer HRT.
    L'Hermite M
    Climacteric; 2013 Aug; 16 Suppl 1():44-53. PubMed ID: 23848491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women.
    Stephenson K; Neuenschwander PF; Kurdowska AK
    Int J Pharm Compd; 2013; 17(1):74-85. PubMed ID: 23627249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormonal replacement therapy (HRT) in postmenopause: a reappraisal.
    Caufriez A
    Ann Endocrinol (Paris); 2007 Sep; 68(4):241-50. PubMed ID: 17651686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.